Beam Therapeutics (BEAM) Payables (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Payables data on file, last reported at $12.3 million in Q1 2026.

• Payables for Q1 2026 came in at $12.3 million, up 59.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.3 million (up 59.58% YoY), and the FY2025 annual result was $10.2 million, up 164.3% from the prior year.
• Payables improved to $12.3 million in Q1 2026 per BEAM's latest filing, from $10.2 million in the prior quarter.
• Over five years, Payables peaked at $14.1 million in Q1 2023 and troughed at $1.6 million in Q4 2023.
• A 5-year average of $7.1 million and a median of $7.0 million in 2022 frame the typical range for Payables.
• The sharpest annual moves came in 2023 and 2025: Payables tumbled 82.09% in 2023, then jumped 175.95% in 2025.
• A 5-year view of Payables shows it stood at $9.0 million in 2022, then plunged by 82.09% to $1.6 million in 2023, then surged by 139.39% to $3.9 million in 2024, then soared by 164.3% to $10.2 million in 2025, then grew by 20.09% to $12.3 million in 2026.
• Business Quant data shows BEAM's Payables at $12.3 million in Q1 2026, $10.2 million in Q4 2025, and $9.5 million in Q3 2025.